Abstract |
Smith-Magenis syndrome (SMS) is a genetic disease ascribed to an interstitial deletion on chromosome 17 (del 17p11); the prevalence is 1/25,000 births. The diagnosis is made on high-resolution karyotype confirmed by FISH. Clinical features include mild dysmorphism, short stature, other malformations (heart, renal, neurologic diseases). Mental retardation is constant; there are major behavioral disturbances and severe sleep disorders. We studied sleep disorders and melatonin secretion in SMS children and we have shown inversion of the circadian rhythm of melatonin, abnormally secreted during the day. This is the first biological model of behavioral and sleep disorder in a genetic disease. Therapeutic approach using beta-blockers in the morning and melatonin in the evening, reset circadian rhythm of melatonin, improve behavior and restore sleep.
|
Authors | H De Leersnyder, M-C de Blois, J-L Bresson, D Sidi, B Claustrat, A Munnich |
Journal | Revue neurologique
(Rev Neurol (Paris))
Vol. 159
Issue 11 Suppl
Pg. 6S21-6
(Nov 2003)
ISSN: 0035-3787 [Print] France |
Vernacular Title | Inversion du rythme circadien de la mélatonine dans le syndrome de Smith-Magenis. |
PMID | 14646795
(Publication Type: Journal Article)
|
Chemical References |
- Adrenergic beta-Antagonists
- Melatonin
|
Topics |
- Abnormalities, Multiple
(genetics, physiopathology)
- Adolescent
- Adrenergic beta-Antagonists
(administration & dosage, therapeutic use)
- Child
- Child, Preschool
- Chromosome Deletion
- Chromosome Disorders
(genetics, physiopathology)
- Chromosomes, Human, Pair 17
(genetics, ultrastructure)
- Chronotherapy
- Circadian Rhythm
- Drug Therapy, Combination
- Female
- Humans
- Intellectual Disability
(genetics, physiopathology)
- Male
- Melatonin
(administration & dosage, metabolism, therapeutic use)
- Pineal Gland
(metabolism)
- Secretory Rate
- Sleep Wake Disorders
(drug therapy, genetics, physiopathology)
- Syndrome
|